Please login to the form below

Not currently logged in
Email:
Password:

tardive dyskinesia

This page shows the latest tardive dyskinesia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

Its KarXT molecule aims to avoid the safety issues that have given existing antipsychotic medicines a bad name, these include tardive dyskinesia, metabolic dysfunction, weight gain, glucose intolerance, sedation and others

Latest news

  • FDA clears Teva's tardive dyskinesia drug Austedo FDA clears Teva's tardive dyskinesia drug Austedo

    FDA clears Teva's tardive dyskinesia drug Austedo. The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza. ... April. Tardive dyskinesia, a neurological disorder characterised by repetitive involuntary movements such as grimacing,

  • Neurocrine bags FDA approval for first tardive dyskinesia drug Neurocrine bags FDA approval for first tardive dyskinesia drug

    Neurocrine bags FDA approval for first tardive dyskinesia drug. Ingrezza edges ahead of Teva’s rival drug Austedo. ... Neurocrine Biosciences has claimed the distinction of getting the first-ever FDA approval for a drug to treat tardive dyskinesia, a

  • FDA approves Teva's Huntington's disease drug at second attempt FDA approves Teva's Huntington's disease drug at second attempt

    tardive dyskinesia, a much larger movement disorder indication, which has no approved therapies in the US. ... It is estimated that around 35, 000 people have HD in the US, but the population with tardive dyskinesia, which often develops as a

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    FDA sets August review date for Teva's movement disorder drug. Could be first approved treatment for tardive dyskinesia. ... Patients with the movement disorder tardive dyskinesia (TD) could have a first approved treatment if the FDA clears Teva's SD-809

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    The metabolites issue is critical for Teva as it is also developing deutetrabenazine for other uses, notably tardive dyskinesia, a much larger indication which has no approved therapies in the US,

More from news
Approximately 7 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics